KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Sabrina Paganoni, Christina N Fournier, Eric A Macklin, Lori B Chibnik, Melanie Quintana, Benjamin R Saville, Michelle A Detry, Matteo Vestrucci, Joe Marion, Anna McGlothlin, Senda Ajroud-Driss, Marianne Chase, Lindsay Pothier, Brittney A Harkey, Hong Yu, Alexander V Sherman, Jeremy M Shefner, Meghan Hall, Gale Kittle, James D Berry, Suma Babu, Jinsy Andrews, Derek Dagostino, Eric Tustison, Elisa Giacomelli, Erica Scirocco, Gustavo Alameda, Eduardo Locatelli, Doreen Ho, Adam Quick, Jonathan Katz, Daragh Heitzman, Stanley H Appel, Sheetal Shroff, Kevin Felice, Nicholas J Maragakis, Zachary Simmons, Timothy M Miller, Nicholas Olney, Michael D Weiss, Stephen A Goutman, Joseph Americo Fernandes, Omar Jawdat, Margaret Ayo Owegi, Laura A Foster, Tuan Vu, Hristelina Ilieva, Daniel S Newman, Ximena Arcila-Londono, Carlayne E Jackson, Shafeeq Ladha, Terry Heiman-Patterson, James B Caress, Andrea Swenson, Amanda Peltier, Richard Lewis, Dominic Fee, Matthew Elliott, Richard Bedlack, Edward J Kasarskis, Lauren Elman, Jeffrey Rosenfeld, David Walk, Courtney McIlduff, Paul Twydell, Eufrosina Young, Kristin Johnson, Kourosh Rezania, Namita A Goyal, Jeffrey A Cohen, Michael Benatar, Vovanti Jones, Jonathan Glass, Jaimin Shah, Said R Beydoun, James P Wymer, Lindsay Zilliox, Shakti Nayar, Gary L Pattee, Jennifer Martinez-Thompson, Brittany Harvey, Shital Patel, Paul Mahoney, Petra W Duda, Merit E Cudkowicz, HEALEY ALS Platform Trial Study Group

JAMA Netw Open 8(2) e2459058

PMID39960672
PMCIDPMC11833520
DOI10.1001/jamanetworkopen.2024.59058
发表日期2025-02-17
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. OBJECTIVE: To determine the effects of zilucoplan, an inhibitor of complement C5, in individuals with ALS. DESIGN, SETTING, AND PARTICIPANTS: Zilucoplan was tested as regimen A of the HEALEY ALS Platform Trial, a phase 2 to 3 multicenter, randomized, double-blind, placebo-controlled perpetual platform clinical trial with sharing of trial infrastructure and placebo data across multiple regimens. Regimen A was conducted from August 17, 2020, to May 4, 2022. A total of 162 participants were randomized to receive zilucoplan (122 [75.3%]) or regimen-specific placebo (40 [24.7%]). An additional 124 concurrently randomized participants were randomized to receive placebo in other regimens. INTERVENTIONS: Eligible participants were randomized in a 3:1 ratio to receive zilucoplan or matching placebo within strata of edaravone and/or riluzole use for a planned duration of 24 weeks. Active drug (zilucoplan, 0.3 mg/kg) and placebo were provided for daily subcutaneous dosing. MAIN OUTCOMES AND MEASURES: The primary end point was change in disease severity from baseline through 24 weeks as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score and survival, analyzed using a bayesian shared-parameter model and reported as disease rate ratio (DRR; <1 indicating treatment benefit). The study included prespecified rules for early stopping for futility. Outcome analyses were performed in the full analysis set comparing the zilucoplan group with the total shared placebo group (n = 164). RESULTS: Among the 162 participants who were randomized (mean [SD] age, 59.6 [11.3]; 99 [61.1%] male), 115 (71.0%) completed the trial. The estimated DRR common to ALSFRS-R and survival was 1.08 (95% credible interval, 0.87-1.31; posterior probability of superiority, 0.24). The trial was stopped early for futility. No unexpected treatment-related risks were identified. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of zilucoplan in ALS, treatment did not alter disease progression. The adaptive platform design of the HEALEY ALS Platform Trial made it possible to test a new investigational product with efficient use of time and resources. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04297683.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Change in Disease Severity Over 24 Weeks as Measured by Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) and Survival (Primary Outcome) A, Boxplots of the ALSFRS-R change from baseline over time for the active treatment (light blue), the regimen placebo (light tan), and the shared placebo (dark tan). The bottom of each box represents the 25th percentile of the ALSFRS-R change from baseline values and the top of the box represents the 75th percentile. The horizontal line within each box represents the median value. The whiskers extend to the most extreme data point that is no further than 1.5 times the length of the box away from the box, with outlier values beyond this range shown by open circles. Solid points are the raw mean values at each visit, with different shapes and colors representing active treatment (light blue circles), the regimen placebo group (light tan squares), and the shared placebo group (dark tan triangles). The solid diagonal lines are the model-estimated change in ALSFRS-R over time, adjusting for covariates. The estimate for the regimen placebo group shares information from the placebo groups in other regimens. The numbers below the panel show the number of participants with known ALSFRS-R outcomes at each visit. The summary excludes all ALSFRS-R data from participants who died or had a death-equivalent event (permanent assisted ventilation [PAV]). ALSFRS-R scores range from 11.0 to 47.0, with higher scores indicating better function. B, Kaplan-Meier curves for death or PAV per arm and the model-estimated exponential curves for the active treatment and pooled placebo groups. The numbers below the panel indicate the number of participants exposed and the number of death or PAV events per arm.

B

survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Study Flow Diagram Participants could have multiple reasons for exclusion from the master protocol and could screen for the master protocol more than once. The most common reasons for exclusion were not meeting the criterion for slow vital capacity of at least 50% (66 of 143 [46% of person-visits]), having a clinically significant unstable medical condition (other than amyotrophic lateral sclerosis [ALS]) that would pose a risk to the participant (44 of 143 [31% of person-visits]), and having used investigational treatments for ALS within 5 half-lives (if known) or 30 days (whichever is longer) prior to the master protocol screening visit (24 of 143 [17% of person-visits]). The 29 participants who completed the regimen in the regimen-specific placebo are included in the 137 shared placebo who completed the study.
非 KM Figure
Figure 3Figure 3.. Study Timeline A, The actual timeline for trial completion after the futility criterion was met at the February 2022 interim analysis. B, The projected timeline for trial completion if interim analyses did not occur and all participants completed the full 24 weeks of the randomized placebo-controlled portion of the regimen. Using the projected dates of trial completion, the sum of all expected visits that would have occurred between the actual and projected last participant last visit (LPLV) was calculated using individual participant visit schedules generated from the electronic data capture system. FPFV indicates first participant first visit; OLE, open-label extension; RCT, randomized clinical trial; and TLR, top line results. a Per the regimen specific appendix, the final study visit for a participant occurred 40 plus or minus 3 days after discontinuing investigational product treatment.
非 KM Figure